From outside, it looks like just another commercial building in downtown L.A., but inside, it's like a cross between a museum and an amusement park attraction.

D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $0.79 per share a year ago.

For decades, data centers were designed with permanence in mind: fixed plans, rigid shapes and predictable life cycles.

A single intravitreal injection of 4D-150 helped patients with wet age-related macular degeneration maintain visual acuity ...